Oncotype DX is a diagnostic test that helps identify which women with early-stage, lymph node negative and estrogen receptor-positive breast cancer are more likely to benefit from adding chemotherapy to their hormonal treatment.
The Oncotype DX test measures the activity of different genes in a woman's breast tissue tumor tissue.
The Oncotype DX test measures the activity of different genes in a woman's breast tissue tumor tissue.
Women with lower (RS) recurrence scores have a lower risk that their cancer will return. These women also have a cancer that is less likely to benefit from chemotherapy. A lower recurrence score does not necessarily mean that there is no chance that the breast cancer will return.
Women with a higher (RS) recurrence score have a stronger chance that their breast cancer will return, but may also benefit largely from chemotherapy. A higher recurrence score does not mean that a woman's breast cancer will definitely return.
